Aptahem AB

27 Aug - 10 Sep 2021Rights issue
Aptahem AB is a biotechnology company whose main business model is to preclinically and clinically develop aptamer-based treatments for life-threatening, acute conditions where coagulation and inflammation interact in the disease process. The aim is to meet the global need for medicines within these conditions.
Read more at the company's website
The offer in summary
Subscription period: 27 August - 10 September 2021
Subscription price: 4.80 SEK per unit
Trading in unit rights: 27 August - 7 September 2021
Issue volume: 61.8 MSEK
Unit: One (1) unit consists of four (4) shares and three (3) warrants of serie TO 7
